SIGIRR is expressed mainly in the cytoplasm and nucleus of prostate epithelial cells, and no significant difference in the cytoplasmic expression of SIGIRR is observed between benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, prostate cancer and metastatic cancer. Here, SIGIRR is linked to prostate carcinoma.